FMP

FMP

Enter

MLND - Millendo T...

photo-url-https://images.financialmodelingprep.com/symbol/MLND.png

Millendo Therapeutics, Inc.

MLND

NASDAQ

Inactive Equity

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

1.06 USD

-0.06000006 (-5.66%)

Build Up Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

1.56B

1.29B

1.17B

1.08B

1.06B

968.65M

881.74M

802.62M

730.61M

665.06M

Operating Cash Flow

-63.85M

-29.78M

-111.53M

-87.16M

3.56M

-45.93M

-41.81M

-38.06M

-34.64M

-31.54M

Cap Ex

-20.54M

-15.49M

-16.53M

-21.96M

-11.89M

-13.73M

-12.5M

-11.38M

-10.35M

-9.43M

Free Cash Flow

-84.39M

-45.27M

-128.06M

-109.13M

-8.34M

-59.66M

-54.31M

-49.43M

-45M

-40.96M

Wacc

12.6

12.6

12.6

12.6

12.6

Pv Lfcf

-52.99M

-42.84M

-34.63M

-28M

-22.63M

Sum Pv Lfcf

-181.09M

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep